Blood Microbiota Modification After Myocardial Infarction Depends Upon Low‐Density Lipoprotein Cholesterol Levels

Amar, Jacques; Lelouvier, Benjamin; Servant, Florence; Lluch, Jérôme; Burcelin, Rémy; Bongard, Vanina; Elbaz, Meyer

doi:10.1161/jaha.118.011797

Cited by 31 publications

(41 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study population included ACS patients with available EDTA-plasma sample from the previously described prospective ACS-cohort (FLORINF, NCT02405468) [10]. Cases (n = 99) were patients who experienced an acute ischemic event and included one week after the acute ischemic phase (hereinafter referred to as ACS).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Identification of a miRNA Based-Signature Associated with Acute Coronary Syndrome: Evidence from the FLORINF Study

Elbaz

Faccini

Laperche

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Background: The discovery of novel biomarkers that improve risk prediction models of acute coronary syndrome (ACS) is needed to better identify and stratify very high-risk patients. MicroRNAs (miRNAs) are essential non-coding modulators of gene expression. Circulating miRNAs recently emerged as important regulators and fine-tuners of physiological and pathological cardiovascular processes; therefore, specific miRNAs expression profiles may represent new risk biomarkers. The aims of the present study were: (i) to assess the changes in circulating miRNAs levels associated with ACS and (ii) to evaluate the incremental value of adding circulating miRNAs to a clinical predictive risk model. Methods and Results: The study population included ACS patients (n = 99) and control subjects (n = 103) at high to very high cardiovascular risk but without known coronary event. Based on a miRNA profiling in a matched derivation case (n = −6) control (n = 6) cohort, 21 miRNAs were selected for validation. Comparing ACS cases versus controls, seven miRNAs were significantly differentially expressed. Multivariate logistic regression analyses demonstrated that among the seven miRNAs tested, five were independently associated with the occurrence of ACS. A receiver operating characteristic curve analysis revealed that the addition of miR-122 + miR-150 + miR-195 + miR-16 to the clinical model provided the best performance with an increased area under the curve (AUC) from 0.882 to 0.924 (95% CI 0.885–0.933, p = 0.003). Conclusions: Our study identified a powerful signature of circulating miRNAs providing additive value to traditional risk markers for ACS.

show abstract

Section: Resultsmentioning

confidence: 99%

“…We carried out a case-control study (FLORINF, NCT02405468) recruited in the Cardiology, Arterial Hypertension and Therapeutic department of Toulouse University Hospital Center, France [10]. Cases were patients (n = 99, men and women) who experienced an acute ischemic event and were included one week after the acute ischemic phase.…”

Section: Study Populationmentioning

confidence: 99%

Identification of a miRNA Based-Signature Associated with Acute Coronary Syndrome: Evidence from the FLORINF Study

Elbaz

Faccini

Laperche

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this regard, recent evidence describes the alteration of gut microbiota in established cardiovascular disease [41]. Besides, myocardial infarction has been reported to modulate the blood microbiota, mediated by the increase of intestinal bacterial translocation [42]. Secondly, Haro et al [9] did not address possible differences between OB and MetS, depending on the associated drug treatments.…”

Section: Discussionmentioning

confidence: 99%

There is No Distinctive Gut Microbiota Signature in the Metabolic Syndrome: Contribution of Cardiovascular Disease Risk Factors and Associated Medication

et al. 2020

View full text Add to dashboard Cite

The gut microbiota (GM) has attracted attention as a new target to combat several diseases, including metabolic syndrome (MetS), a pathological condition with many factors (diabetes, obesity, dyslipidemia, hypertension, etc.) that increase cardiovascular disease (CVD) risk. However, the existence of a characteristic taxonomic signature associated with obesity-related metabolic dysfunctions is under debate. To investigate the contribution of the CVD risk factors and(or) their associated drug treatments in the composition and functionality of GM in MetS patients, we compared the GM of obese individuals (n = 69) vs. MetS patients (n = 50), as well as within patients, depending on their treatments. We also explored associations between medication, GM, clinical variables, endotoxemia, and short-chain fatty acids. Poly-drug treatments, conventional in MetS patients, prevented the accurate association between medication and GM profiles. Our results highlight the heterogeneity of taxonomic signatures in MetS patients, which mainly depend on the CVD risk factors. Hypertension and(or) its associated medication was the primary trait involved in the shaping of GM, with an overabundance of lipopolysaccharide-producing microbial groups from the Proteobacteria phylum. In the context of precision medicine, our results highlight that targeting GM to prevent and(or) treat MetS should consider MetS patients more individually, according to their CVD risk factors and associated medication.

show abstract

“…The blood samples have also higher genus richness and different composition suggesting that the technical contamination had no significant impact. The presence of a specific blood microbiome has already been demonstrated in several diseases such as chronic kidney diseases, liver fibrosis, diabetes mellitus or cardiovascular events (5,14,15).…”

Section: Discussionmentioning

confidence: 99%

“…It has long been thought that blood is a sterile environment. However, recent sequence-based studies have revealed that changes in blood microbiota are associated with various diseases (4,5). Studying blood microbiota is particularly interesting because it is a reflexion of various microbiota (gut, oral, nasal) and it allows thus to determine the presence of bacteria or bacterial DNA that have passed the mucosal barrier.…”

Section: Introductionmentioning

confidence: 99%

Specific microbiome profile in Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA).

Desbois¹,

Ciocan

Saadoun

et al. 2020

Preprint

View full text Add to dashboard Cite

Objectives: There is increasing evidence of a close link between microbiota and inflammatory diseases. Microbiota has never been studied in large vessel vasculitis (LVV). We aimed to analyse the blood microbiome profile of patients with LVV [Takayasu arteritis (TAK) or giant cell arteritis (GCA)] and healthy donors (HD). Methods : We studied blood samples of 13 patients with TAK (20 samples), 9 (11 samples) with GCA and 15 HD. The blood microbiome profile was assessed by sequencing of the 16S rDNA blood bacterial DNA. Linear Discriminant Analysis (LDA) coupled with effect size measurement (LEfSe) was used to analyse the differences in the blood microbiome profile between the groups. Results: Samples of TAK patients showed an increase in the levels of Clostridia, Cytophagia and Deltaproteobacteria and a decrease in Bacilli at the class level as compared to HD (LDA>2, p<0.05). Active compared to inactive TAK patients had significantly lower levels of Staphylococcus. Samples of GCA patients showed an increased abundance of Rhodococcus and an unidentified member of the Cytophagaceae family. Microbiota of TAK compared to GCA patients showed higher levels of Candidatus Aquiluna and Cloacibacterium (LDA>2; p<0.05). Differences in blood microbiome were also associated with a shift of bacterial predicted metabolic functions in TAK compared to HD. Similar results were also found in active compared to inactive TAK patients. In conclusion , TAK patients showed a specific blood microbiome profile as compared to healthy controls and GCA patients. Among TAK patients, significant changes of blood microbiome profile were associated with specific metabolic functions.

show abstract

Blood Microbiota Modification After Myocardial Infarction Depends Upon Low‐Density Lipoprotein Cholesterol Levels

Cited by 31 publications

References 31 publications

Identification of a miRNA Based-Signature Associated with Acute Coronary Syndrome: Evidence from the FLORINF Study

Identification of a miRNA Based-Signature Associated with Acute Coronary Syndrome: Evidence from the FLORINF Study

There is No Distinctive Gut Microbiota Signature in the Metabolic Syndrome: Contribution of Cardiovascular Disease Risk Factors and Associated Medication

Specific microbiome profile in Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA).

Contact Info

Product

Resources

About